PMID- 9180302
OWN - NLM
STAT- MEDLINE
DCOM- 19970626
LR  - 20190914
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 11
IP  - 5
DP  - 1997 May
TI  - Characteristic pattern of chromosomal gains and losses in marginal zone B cell 
      lymphoma detected by comparative genomic hybridization.
PG  - 747-58
AB  - Marginal zone B cell lymphoma (MZBCL) represents a distinct subtype of B cell 
      non-Hodgkin's lymphoma, which has been recently recognized and defined as a 
      disease entity. We investigated 25 cases (18 at primary diagnosis and seven 
      during the course of disease) of MZBCL by comparative genomic hybridization (CGH) 
      and compared these results with cytogenetic, fluorescence in situ hybridization 
      (FISH), and Southern blot data. Twenty of the 25 cases (80%) showed gains (total 
      49) or losses (total 15) of genetic material. In extranodal, nodal, and splenic 
      MZBCL, material of chromosomes 3 (52% of cases), 18 (32%), X (24%), and 1q (16%) 
      was most frequently gained, whereas losses predominantly involved chromosomes 17 
      (16%) and 9 (12%). High-level amplifications involving the regions 18q21-23 and 
      18q21-22, respectively, were detected in two cases. Gains of chromosomes 1q and 
      8q and losses of chromosome 17 or 17p occurred more frequently in relapsed or 
      progressive lymphomas. For all of the frequently affected chromosomes, CGH 
      allowed narrowing of the relevant subregions including 3q21-23, 3q25-29 and 
      18q21-23. By Southern blot analysis, the BCL2, BCL6, and CMYC proto-oncogenes 
      were found to be a part of the over-represented regions in two cases, one case, 
      and two cases, respectively, with gains involving 18q, 3q or 8q. In 13 cases, CGH 
      revealed chromosomal imbalances which were not detected by cytogenetic analysis 
      but could be confirmed by FISH or Southern blot analysis in all cases 
      investigated. On the other hand, CGH failed to detect trisomy 3, trisomy 18, and 
      deletion 7q in three cases with a low proportion of tumor cells bearing these 
      abnormalities, as shown by interphase FISH. The characteristic pattern of 
      chromosomal gains and losses detected in this study confirms the distinct nature 
      of MZBCL and may point to chromosomal regions involved in the pathogenesis of 
      these neoplasms.
FAU - Dierlamm, J
AU  - Dierlamm J
AD  - Center for Human Genetics and Flanders Institute of Biotechnology, University of 
      Leuven, Belgium.
FAU - Rosenberg, C
AU  - Rosenberg C
FAU - Stul, M
AU  - Stul M
FAU - Pittaluga, S
AU  - Pittaluga S
FAU - Wlodarska, I
AU  - Wlodarska I
FAU - Michaux, L
AU  - Michaux L
FAU - Dehaen, M
AU  - Dehaen M
FAU - Verhoef, G
AU  - Verhoef G
FAU - Thomas, J
AU  - Thomas J
FAU - de Kelver, W
AU  - de Kelver W
FAU - Bakker-Schut, T
AU  - Bakker-Schut T
FAU - Cassiman, J J
AU  - Cassiman JJ
FAU - Raap, A K
AU  - Raap AK
FAU - De Wolf-Peeters, C
AU  - De Wolf-Peeters C
FAU - Van den Berghe, H
AU  - Van den Berghe H
FAU - Hagemeijer, A
AU  - Hagemeijer A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosome Aberrations
MH  - *Chromosome Deletion
MH  - *Chromosome Mapping
MH  - DNA-Binding Proteins/genetics
MH  - Female
MH  - Genes, bcl-2
MH  - Genes, myc
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Lymphoma, B-Cell/drug therapy/*genetics/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Proto-Oncogene Proteins/genetics
MH  - Proto-Oncogene Proteins c-bcl-6
MH  - *Proto-Oncogenes
MH  - Survival Rate
MH  - Transcription Factors/genetics
MH  - Trisomy
EDAT- 1997/05/01 00:00
MHDA- 1997/05/01 00:01
CRDT- 1997/05/01 00:00
PHST- 1997/05/01 00:00 [pubmed]
PHST- 1997/05/01 00:01 [medline]
PHST- 1997/05/01 00:00 [entrez]
AID - 10.1038/sj.leu.2400635 [doi]
PST - ppublish
SO  - Leukemia. 1997 May;11(5):747-58. doi: 10.1038/sj.leu.2400635.